pre-IPO PHARMA

COMPANY OVERVIEW

Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. Aerovate was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.


LOCATION

  • Boston, MA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease

  • WEBSITE

    https://www.aerovatetx.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    atlas-venture cormorant-asset-management osage-university-partners ra-capital sofinnova-investments surveyor


    PRESS RELEASES


    May 18, 2021

    Aerovate Therapeutics Appoints Timothy Noyes as Chief Executive Officer


    For More Press Releases


    Google Analytics Alternative